Format

Send to

Choose Destination
See comment in PubMed Commons below
Invest New Drugs. 1992 Nov;10(4):331-5.

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Author information

1
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.

Abstract

We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

PMID:
1336771
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center